Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma
Canadian Urological Association Journal · 21.07.2026 · 20 (11)
DOI: 10.5489/cuaj.9588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Urological Association Journal, online erschienen am 21.07.2026. Verfasst von Hangcheng Fu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States.
Abstract (Originalsprache)
Introduction
Penile squamous cell carcinoma (PSCC), although rare, presents significant morbidity. Current guidelines recommend lymph node dissection (LND) or lymph node biopsy on a risk-stratified basis for intermediate- or high-risk patients; however, survival benefits of LND in clinically node-negative patients need further exploration.
Methods
Patients with T2+N0M0 PSCC were identified from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). Inclusion required histologically confirmed squamous cell carcinoma localized to the penis. Patients with unavailable staging or unknown followup were excluded. Chi-square tests, Kaplan-Meier survival curves, and multivariable Cox regression analyses assessed disease-specific survival (DSS).
Results
A total of 825 patients were analyzed. The cohort predominantly included non-Hispanic White (65.2%) and Hispanic (22.3%) patients, with a median age of 69 years. Most patients were married (57.2%), while few received radiation (6.6%) or chemotherapy (3.5%). Only 23.5% underwent LND, with no significant variation across T stages. Median followup was 60 months. Chemotherapy usage increased significantly with advancing T stage (p=0.009), whereas radiation did not. LND significantly improved DSS overall (p
Autor:innen und Institutionen
- Department of Urology, University of Louisville School of Medicine, Louisville, KY, United States.
Zitieren
APA
Fu, H., George, A., Anele, U., Said, M., Messer, J., & Ankem, M. K. (2026). Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma. Canadian Urological Association Journal, 20(11). https://doi.org/10.5489/cuaj.9588
Vancouver
Fu H, George A, Anele U, Said M, Messer J, Ankem MK. Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma. Canadian Urological Association Journal. 2026;20(11). doi:10.5489/cuaj.9588
BibTeX
@article{Fu2026,
author = {Fu, Hangcheng and George, Abigail and Anele, Uzoma and Said, Mohammed and Messer, Jamie and Ankem, Murali K},
title = {Survival benefit and utilization disparities of lymph node dissection in clinically node-negative T2+ penile squamous cell carcinoma},
journal = {Canadian Urological Association Journal},
year = {2026},
volume = {20},
number = {11},
doi = {10.5489/cuaj.9588}
}
EUVIMED